Healthcare
Hansa Biopharma AB (publ)(HNSBF)
Live Price
Offline$2.90
+0.00% today
Window Change
+0.00%
Window
Apr 16, 2026 β Jun 23, 2026
- Market Cap
- $2.21B
- Revenue Growth
- +29.7%
- EPS Growth
- +49.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 49 bars Β· Apr 16, 2026 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hansa Biopharma AB (publ) (HNSBF) is a Healthcare stock with a market cap of $2.21B and listed on OTC. The stock last traded around $2.90 and up 0.0% across the available one-year price window (Apr 16, 2026 β Jun 23, 2026). Baseline metrics include revenue growth of +29.7%, EPS growth of +49.0%, a dividend yield of 0.0%. What stands out right now is revenue +29.7%, EPS +49.0%, free cash flow +18.6% with operating margin -299.1% and ROIC -60.0%. Valuation already assumes a fairly strong business story at price/sales 11.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines HNSBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+29.7% vs +7.6% peer median
Operating Margin
Below sector median
-299.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +29.7% and EPS at +49.0%, with operating margin around -299.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | β | +0.0% | +0.0% | +0.0% |
2026 Feb 11, 2026 | -2.8% | +0.0% | +0.0% | +0.0% |
2025 Oct 30, 2025 | -0.8% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
HNSBF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HNSBF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HNSBF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HNSBF and SPY.
Company Overview
Hansa Biopharma AB (publ)
Other OTC
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain BarrΓ© syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
- Leadership
- Renee Aguiar-Lucander
- IPO Date
- Mar 25, 2015
- Employees
- 138
- Street Address
- PO Box 785
- Mailing
- Lund, 220 07
- Region
- Lund, SE
- Reporting Currency
- USD
- Investor Line
- 46 46 16 56 70
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 11.6
- Price/Book
- β
Growth
- Revenue
- +29.7%
- EPS
- +49.0%
- Free Cash Flow
- +18.6%
Profitability
- Gross Margin
- 59.7%
- Operating Margin
- -299.1%
- Net Margin
- -361.4%
- ROE
- 201.6%
- ROIC
- -60.0%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 3.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.